- cafead Feb 09, 2022 at 10:02: AM
via As Big Pharma races to beef up their franchises in cardiometabolic diseases, a much smaller player wants to give them a run for their money,
And Rivus Pharmaceuticals, a tiny biotech with only seven full-time employees, says it has the preliminary data to suggest that its lead drug can play a big role in large indications like heart failure with preserved ejection fraction, type 2 diabetes and non-alcoholic steatohepatitis (NASH) — the last being a notorious wasteland for drug development efforts.
article source
And Rivus Pharmaceuticals, a tiny biotech with only seven full-time employees, says it has the preliminary data to suggest that its lead drug can play a big role in large indications like heart failure with preserved ejection fraction, type 2 diabetes and non-alcoholic steatohepatitis (NASH) — the last being a notorious wasteland for drug development efforts.
article source